Latest Breaking News On - Mondher mahjoubi - Page 10 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Innate Pharma First Quarter 2021 Report INNATE PHARMAMay 11, 2021 GMT Lacutamab TELLOMAK trial progresses as KIR3DL2-expressing mycosis fungoides cohort advances to Stage 2 after positive early signal Company’s first NK cell engager selected by Sanofi as drug candidate for development Cash position of €181.7 million¹  as of March 31, 2021 MARSEILLE, France, May 11, 2021 (GLOBE NEWSWIRE) Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its revenue and cash position for the three-month period ending March 31, 2021. “This quarter, we have continued to execute against our strategy, successfully progressing the lacutamab TELLOMAK trial in the mycosis fungoides cohort while also advancing our first NK cell engager with our partner, Sanofi,” said Mondher Mahjoubi, Chief Executive Officer of Innate Pha

Mondher mahjoubiBristol myers squibbNovo nordiskFederation of clinical immunology societiesExchange commissionFrench financial markets authorityCompany annual report on formInternational conference on malignant lymphomaLymphoma study associationEuronext parisChief executive officerInnate pharmaInternational conferenceMalignant lymphomaClinical immunology societiesPrivate securities litigation reform act